90,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Bought by B Group Inc.

B Group Inc. bought a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 4th quarter, HoldingsChannel.com reports. The fund bought 90,000 shares of the company’s stock, valued at approximately $6,260,000. Structure Therapeutics comprises approximately 4.6% of B Group Inc.’s portfolio, making the stock its 8th largest position.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Avoro Capital Advisors LLC boosted its stake in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after acquiring an additional 1,150,000 shares in the last quarter. Verition Fund Management LLC boosted its stake in Structure Therapeutics by 98.6% during the fourth quarter. Verition Fund Management LLC now owns 78,149 shares of the company’s stock worth $5,435,000 after acquiring an additional 38,800 shares in the last quarter. PEAK6 LLC bought a new position in Structure Therapeutics during the fourth quarter worth $553,000. MML Investors Services LLC bought a new position in Structure Therapeutics during the fourth quarter worth $544,000. Finally, Maven Securities LTD bought a new position in Structure Therapeutics during the fourth quarter worth $1,391,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Trading Down 0.4%

Shares of Structure Therapeutics stock opened at $42.91 on Wednesday. The stock has a fifty day simple moving average of $43.22 and a 200 day simple moving average of $57.45. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90. The company has a market capitalization of $3.05 billion, a P/E ratio of -49.32 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on GPCR shares. Citizens Jmp dropped their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research note on Friday, February 27th. HC Wainwright dropped their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Wolfe Research started coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Finally, Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.